Brett Elizabeth A, Aitzetmüller Matthias M, Sauter Matthias A, Huemer Georg M, Machens Hans-Günther, Duscher Dominik
Department of Plastic and Hand Surgery, Technical University of Munich, Munich 81675, Germany.
Section of Plastic and Reconstructive Surgery, Kepler University Hospital Linz, Linz 4020, Austria.
Oncotarget. 2018 Jun 12;9(45):27895-27906. doi: 10.18632/oncotarget.25602.
Breast reconstruction proceeding cancer treatment carries risk, regardless of the type of surgery. From fat grafting, to flap placement, to implants, there is no guarantee that reconstruction will not stimulate breast cancer recurrence. Research in this field is clearly divided into two parts: scientific interventional studies and clinical retrospective evidence. The reconstructive procedure offers hypoxia, a wound microenvironment, bacterial load, adipose derived stem cells; agents shown experimentally to cause increased cancer cell activity. This is compelling scientific evidence which serves to bring uncertainty and fear to the reconstructive procedure. In the absence of clinical evidence, this laboratory literature landscape is now informing surgical choices. Curiously, clinical studies have not shown a clear link between breast cancer recurrence and reconstructive surgery. Where does that leave us? This review aims to analyze the science and the surgery, thereby understanding the oncological fear which accompanies breast cancer reconstruction.
癌症治疗后的乳房重建手术存在风险,无论手术类型如何。从脂肪移植到皮瓣移植再到植入物,都不能保证重建手术不会刺激乳腺癌复发。该领域的研究明显分为两部分:科学干预研究和临床回顾性证据。重建手术会造成缺氧、伤口微环境、细菌负荷以及脂肪来源干细胞,这些因素在实验中显示会导致癌细胞活性增加。这是令人信服的科学证据,给重建手术带来了不确定性和恐惧。在缺乏临床证据的情况下,目前这些实验室文献正影响着手术选择。奇怪的是,临床研究并未表明乳腺癌复发与重建手术之间存在明确关联。那我们该何去何从?本综述旨在分析相关科学和手术情况,从而理解伴随乳腺癌重建而来的肿瘤学方面的担忧。